# NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

> **NCT04055428** · PHASE2 · RECRUITING · sponsor: **University of Alabama at Birmingham** · enrollment: 200 (estimated)

## Conditions studied

- Diabetes Mellitus
- Cardiovascular Diseases
- Insulin Sensitivity/Resistance
- Metabolic Disease
- Natriuretic Peptides
- Metabolism
- Energy Expenditure

## Interventions

- **DRUG:** Sacubitril, Valsartan 97-103 mg Oral Tablet
- **DRUG:** Valsartan 160 mg
- **OTHER:** Intravenous Glucose Tolerance Test
- **DIETARY_SUPPLEMENT:** Standardized Meals
- **OTHER:** Exercise capacity VO2 maximum determination

## Key facts

- **NCT ID:** NCT04055428
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055428, "NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04055428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*